Effects of gastrin and difluoromethylornithine on growth of human colon cancer

Jill Palmer Smith, Scott T. Kramer, Laurence M. Demers

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr). In vivo, mice bearing the tumor treated with pentagastrin had larger tumors with higher ornithine decarboxylase activity and polyamine content (P<0.05) than mice not treated with pentagastrin. Difluoromethylornithine treatment significantly decreased ornithine decarboxylase in both the pentagastrin-treated and the untreated animals; however, DFMO had no effect on tumor volume, weight, protein, or DNA content. In cell culture, gastrin treatment increased WiDr cell number and [3H]thymidine incorporation in the presence or absence of serum. In serum-free conditions, however, gastrin stimulated cell growth without concomitantly increasing ODC activity. DFMO, on the other hand, decreased both ODC activity and growth. These studies suggest that the trophic effect of gastrin on WiDr human colon cancer is independent of ODC activity. Since gastrin treatment increased ODC activity in vivo, gastrin may interact in vitro with other factors present in serum that can alter ODC activity.

Original languageEnglish (US)
Pages (from-to)520-528
Number of pages9
JournalDigestive Diseases and Sciences
Volume38
Issue number3
DOIs
StatePublished - Mar 1 1993

Fingerprint

Eflornithine
Gastrins
Colonic Neoplasms
Pentagastrin
Growth
Ornithine Decarboxylase
Tumor Burden
Serum
Gastrin-Secreting Cells
Polyamines
Thymidine
Neoplasms
Colon
Cell Culture Techniques
Cell Count
Carcinoma
DNA
Proteins

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Smith, Jill Palmer ; Kramer, Scott T. ; Demers, Laurence M. / Effects of gastrin and difluoromethylornithine on growth of human colon cancer. In: Digestive Diseases and Sciences. 1993 ; Vol. 38, No. 3. pp. 520-528.
@article{08ffe5f994794b439d2b1a43deef1069,
title = "Effects of gastrin and difluoromethylornithine on growth of human colon cancer",
abstract = "The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr). In vivo, mice bearing the tumor treated with pentagastrin had larger tumors with higher ornithine decarboxylase activity and polyamine content (P<0.05) than mice not treated with pentagastrin. Difluoromethylornithine treatment significantly decreased ornithine decarboxylase in both the pentagastrin-treated and the untreated animals; however, DFMO had no effect on tumor volume, weight, protein, or DNA content. In cell culture, gastrin treatment increased WiDr cell number and [3H]thymidine incorporation in the presence or absence of serum. In serum-free conditions, however, gastrin stimulated cell growth without concomitantly increasing ODC activity. DFMO, on the other hand, decreased both ODC activity and growth. These studies suggest that the trophic effect of gastrin on WiDr human colon cancer is independent of ODC activity. Since gastrin treatment increased ODC activity in vivo, gastrin may interact in vitro with other factors present in serum that can alter ODC activity.",
author = "Smith, {Jill Palmer} and Kramer, {Scott T.} and Demers, {Laurence M.}",
year = "1993",
month = "3",
day = "1",
doi = "10.1007/BF01316509",
language = "English (US)",
volume = "38",
pages = "520--528",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Kluwer Academic Publishers-Plenum Publishers",
number = "3",

}

Effects of gastrin and difluoromethylornithine on growth of human colon cancer. / Smith, Jill Palmer; Kramer, Scott T.; Demers, Laurence M.

In: Digestive Diseases and Sciences, Vol. 38, No. 3, 01.03.1993, p. 520-528.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of gastrin and difluoromethylornithine on growth of human colon cancer

AU - Smith, Jill Palmer

AU - Kramer, Scott T.

AU - Demers, Laurence M.

PY - 1993/3/1

Y1 - 1993/3/1

N2 - The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr). In vivo, mice bearing the tumor treated with pentagastrin had larger tumors with higher ornithine decarboxylase activity and polyamine content (P<0.05) than mice not treated with pentagastrin. Difluoromethylornithine treatment significantly decreased ornithine decarboxylase in both the pentagastrin-treated and the untreated animals; however, DFMO had no effect on tumor volume, weight, protein, or DNA content. In cell culture, gastrin treatment increased WiDr cell number and [3H]thymidine incorporation in the presence or absence of serum. In serum-free conditions, however, gastrin stimulated cell growth without concomitantly increasing ODC activity. DFMO, on the other hand, decreased both ODC activity and growth. These studies suggest that the trophic effect of gastrin on WiDr human colon cancer is independent of ODC activity. Since gastrin treatment increased ODC activity in vivo, gastrin may interact in vitro with other factors present in serum that can alter ODC activity.

AB - The effect of difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase activity, was evaluated in vivo and in vitro on the growth of a gastrin-sensitive human colon carcinoma (WiDr). In vivo, mice bearing the tumor treated with pentagastrin had larger tumors with higher ornithine decarboxylase activity and polyamine content (P<0.05) than mice not treated with pentagastrin. Difluoromethylornithine treatment significantly decreased ornithine decarboxylase in both the pentagastrin-treated and the untreated animals; however, DFMO had no effect on tumor volume, weight, protein, or DNA content. In cell culture, gastrin treatment increased WiDr cell number and [3H]thymidine incorporation in the presence or absence of serum. In serum-free conditions, however, gastrin stimulated cell growth without concomitantly increasing ODC activity. DFMO, on the other hand, decreased both ODC activity and growth. These studies suggest that the trophic effect of gastrin on WiDr human colon cancer is independent of ODC activity. Since gastrin treatment increased ODC activity in vivo, gastrin may interact in vitro with other factors present in serum that can alter ODC activity.

UR - http://www.scopus.com/inward/record.url?scp=0027465412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027465412&partnerID=8YFLogxK

U2 - 10.1007/BF01316509

DO - 10.1007/BF01316509

M3 - Article

C2 - 8444085

AN - SCOPUS:0027465412

VL - 38

SP - 520

EP - 528

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -